Vise Technologies’s Neurocrine Biosciences NBIX Stock Holding History

Vise Technologies’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$200K	Hold	1,412	–	–	﹤0.01%	1383
2025 Q4	$200K	Buy	+1,412	New	+$205K	﹤0.01%	1395

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vise Technologies's NBIX Position: Q1 2026 in Review

Vise Technologies held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 1,412 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

Vise Technologies first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Vise Technologies held 1,412 shares of Neurocrine Biosciences worth $200K as of Q1 2026.
Vise Technologies left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up ﹤0.01% of Vise Technologies's portfolio in Q1 2026, its #1383 holding.
Vise Technologies first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.